Haematologica:ALK阳性间变性大细胞淋巴瘤的特征是重排ALK基因拷贝数增加

2017-07-13 xiaoxiao MedSci原创

间变性大细胞淋巴瘤(anaplastic large cell lymphoma , ALCL) 亦称 ki-1 淋巴瘤,细胞形态待殊,类似 R-S 细胞,有时可与霍奇金淋巴瘤和恶性组织细胞病混淆。细胞呈 CD30 + ,亦即 Ki-1(+), 常有t(2;5)染色体异常,临床常有皮肤侵犯,伴或不伴淋巴结及其他结外部位病变。免疫表型可为 T 细胞型。 约半数的间变性大细胞淋巴瘤(ALCL

间变性大细胞淋巴瘤(anaplastic large cell lymphoma , ALCL) 亦称 ki-1 淋巴瘤,细胞形态待殊,类似 R-S 细胞,有时可与霍奇金淋巴瘤和恶性组织细胞病混淆。细胞呈 CD30 + ,亦即 Ki-1(+), 常有t(2;5)染色体异常,临床常有皮肤侵犯,伴或不伴淋巴结及其他结外部位病变。免疫表型可为 T 细胞型。 

约半数的间变性大细胞淋巴瘤(ALCL)病人中存在间变性淋巴瘤激酶(anaplasticlymphomakinase,ALK)基因异常,ALK蛋白的异常激活使ALK阳性ALCL具有其典型的临床病理特征,并为ALK阳性ALCL的治疗提供新的靶点,提示ALK阳性ALCL的淋巴瘤可归类为一独立病种。

ALK阳性间变性大细胞淋巴瘤的特点是2p23/ALK畸变,包括:约80%的患者存在经典的t(2;5)(P23;Q35)/NPM1-ALK基因重排,在其余情况下发生t(2p23/ALK)转位或倒转。ALK融合基因对嵌合蛋白及其亚细胞定位的活化起着关键作用。利用各种分子生物学技术,研究人员在最新诊断的8例细胞质中仅有ALK表达的间变性大细胞淋巴瘤患者中观察了ALK融合情况。

研究人员发现存在下列基因与ALK融合,包括EEF1G(1例),RNF213/ALO17(1例),ATIC(4例)和TPM3(2例)。值得注意的是,所有病例均有重排ALK基因拷贝数增加,这是从来没有在NPM1-ALK阳性淋巴瘤中观察到的。研究人员推测,这可能是由于与ALK融合的多种基因的表达水平低和/或致癌性低。事实上,与NPM1相比,除了EEF1G基因外的所有可融合基因在正常和恶性T细胞均表达较低。

此外,研究人员还使用CRISPR/Cas9基因编辑技术在Ba/F3细胞中探讨了内源性Npm1-Alk和Atic-Alk融合的转化潜能。结果发现, Npm1-Alk比Atic-Alk有更强的转化潜能,同时在一个较长的培养周期后,研究人员观察到了Atic-Alk的亚克隆增加,而在Npm1-Alk基因中未发现。

总之,本研究的数据表明,非经典NPM1-ALK融合,而是多种ATIC-ALK融合(如RNF213-ALK和TPM3-ALK)导致的淋巴瘤,需要增加ALK杂合基因的量来弥补相对较低的嵌合基因及其表达和信号特性的不足。

原始出处:

van de Krogt JA, Vanden Bempt M,et al.ALK-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.Haematologica. 2017 Jun 28. pii: haematol.2016.146571. doi: 10.3324/haematol.2016.146571. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-12-30 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2018-04-15 changfy
  6. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-15 fengyi812
  7. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-15 huangdf
  8. [GetPortalCommentsPageByObjectIdResponse(id=1702416, encodeId=4ae51e024164d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed May 16 04:18:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987527, encodeId=4fa5198e5279f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2323, encryptionId=540623233e, topicName=ALK阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Dec 30 00:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984436, encodeId=77331984436a0, content=<a href='/topic/show?id=01aa9e51653' target=_blank style='color:#2F92EE;'>#阳性间变性大细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97516, encryptionId=01aa9e51653, topicName=阳性间变性大细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Sat Feb 17 01:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983903, encodeId=dfc41983903d2, content=<a href='/topic/show?id=3a375629858' target=_blank style='color:#2F92EE;'>#拷贝数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56298, encryptionId=3a375629858, topicName=拷贝数)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Jun 02 06:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008280, encodeId=27802008280de, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sun Apr 15 19:18:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317321, encodeId=1b8c131e32130, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463545, encodeId=f02a1463545f5, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Jul 15 07:18:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221904, encodeId=b63a2219048d, content=签到学习了很多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Thu Jul 13 16:41:19 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-13 Chongyang Zhang

    签到学习了很多人

    0

相关资讯

Am J Hematol:依维莫司治疗复发或难治性惰性淋巴瘤疗效如何

复发性惰性淋巴瘤通常会对化学免疫疗法产生耐药,需要新的疗法来治疗。靶向多种类型淋巴瘤PI3K/mTOR通路的疗法已经显示出临床前和临床疗效,为检验复发性/难治性惰性淋巴瘤治疗策略提供了理论基础。2017年5月,发表在《Am J Hematol》的一项研究调查了口服mTORC1抑制剂依维莫司治疗复发或难治性惰性淋巴瘤的疗效。

NEJM:下肢无力与感觉迟钝,最后诊断竟然是……?

MEJM的每期病例,其经典性不必赘述,看看这次又是什么样的离奇病例以及如何抽丝剥茧?

FDA批准检测白血病和淋巴瘤的试剂上市

日前,美国食品和药物管理局(FDA)批准ClearLLab试剂(T1,T2,B1,B2,M)上市。这是首个用于流式细胞术使用的授权测试,可帮助检测某些白血病和淋巴瘤,包括慢性白血病、急性白血病、非霍奇金淋巴瘤、骨髓瘤、骨髓增生异常综合征(MDS)和骨髓增生性肿瘤(MPN)。

表观遗传药物淋巴瘤显示积极疗效

表观遗传学因为控制致癌、抑癌基因表达所以一度被认为是一个重要的抗肿瘤研究方向。EZH2是组蛋白甲基转移酶的一种,负责甲基化H3组蛋白第27位赖氨酸(H3K27),H3K27甲基化后引发多个致癌基因的表达。EZH2是一个叫做PRC2的多蛋白复合物的酶部分,在胚胎发育时很活跃,成人后活性大大下降。EZH2在多种肿瘤有增活变异,在FL、DLBCL变异率为15-20%。Tazemetostat是首创EZH

SCI TRANSL MED:淋巴瘤靶向治疗新突破

作者研究了由SESTRIN1缺失导致的肿瘤发生机制,确定了SESTRIN1和EZH2之间的机械连接,这种机械连接本质上是一种表观遗传修饰,并在多个癌症类型中扮演重要角色。研究人员证明了靶向EZH2的有效性取决于SESTRIN1的遗传和表观遗传状态,并且还报道了EZH2上的突变可以使癌细胞对其他靶向治疗敏感。

Cancer Cell:中国科大等首次揭示T细胞淋巴瘤的表观遗传调控机制

近日,中国科学技术大学生命科学学院医学中心及中科院天然免疫和慢性疾病重点实验室教授瞿昆课题组联合美国斯坦福大学Howard Chang实验室,首次揭示了T细胞淋巴瘤(CTCL)的表观遗传调控机制。该研究成果以Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors 为题发表在6月15日的国际期刊《癌细胞》(Cancer Cell)上。

<